{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T09:28:53Z","timestamp":1789810133004,"version":"4.0.1"},"reference-count":267,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","license":[{"start":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T00:00:00Z","timestamp":1722211200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/ http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>The objective of this review was to examine the role of adverse drug events (ADEs) caused by pharmacological interventions in cost-effectiveness models for diabetes mellitus, diabetic retinopathy, and diabetic macular edema.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Guidelines for economic evaluation recognize the importance of including ADEs in the analysis, but in practice, consideration of ADEs in cost-effectiveness models seem to be vague. Inadequate inclusion of these harmful outcomes affects the reliability of the results, and the information provided by economic evaluation could be misleading. Reviewing whether and how ADEs are incorporated in cost-effectiveness models is necessary to understand the current practices of economic evaluation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Inclusion criteria:<\/jats:title>\n                    <jats:p>Studies included were published between 2011\u20132022 in English, representing cost-effectiveness analyses using modeling framework for pharmacological interventions in the treatment of diabetes mellitus, diabetic retinopathy, or diabetic macular edema. Other types of analyses and other types of conditions were excluded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>The databases searched included MEDLINE (PubMed), CINAHL (EBSCOhost), Scopus, Web of Science Core Collection, and NHS Economic Evaluation Database. Gray literature was searched via the National Institute for Health and Care Excellence, European Network for Health Technology Assessment, the National Institute for Health and Care Research, and the International Network of Agencies for Health Technology Assessment. The search was conducted on January 1, 2023. Titles and abstracts were screened for inclusion by 2 independent reviewers. Full-text review was conducted by 3 independent reviewers. A data extraction form was used to extract and analyze the data. Results were presented in tabular format with a narrative summary, and discussed in the context of existing literature and guidelines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 242 reports were extracted and analyzed in this scoping review. For the included analyses, type 2 diabetes was the most common disease (86%) followed by type 1 diabetes (10%), diabetic macular edema (9%), and diabetic retinopathy (0.4%). The majority of the included analyses used a health care payer perspective (88%) and had a time horizon of 30 years or more (75%). The most common model type was a simulation model (57%), followed by a Markov simulation model (18%). Of the included cost-effectiveness analyses, 26% included ADEs in the modeling, and 13% of the analyses excluded them. Most of the analyses (61%) partly considered ADEs; that is, only 1 or 2 ADEs were included. No difference in overall inclusion of ADEs between the different conditions existed, but the models for diabetic retinopathy and diabetic macular edema more often omitted the ADE-related impact on quality of life compared with the models for diabetes mellitus. Most analyses included ADEs in the models as probabilities (55%) or as a submodel (40%), and the most common source for ADE incidences were clinical trials (65%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>The inclusion of ADEs in cost-effectiveness models is suboptimal. The ADE-related costs were better captured than the ADE-related impact on quality of life, which was most pronounced in the models for diabetic retinopathy and diabetic macular edema. Future research should investigate the potential impact of ADEs on the results, and identify the criteria and policies for practical inclusion of ADEs in economic evaluation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Supplemental digital content:<\/jats:title>\n                    <jats:p>A Finnish-language version of the abstract of this review is available: http:\/\/links.lww.com\/SRX\/A68.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.11124\/jbies-23-00511","type":"journal-article","created":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T04:00:09Z","timestamp":1721966409000},"page":"2194-2266","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Adverse drug events in cost-effectiveness models of pharmacological interventions for diabetes, diabetic retinopathy, and diabetic macular edema: a scoping review"],"prefix":"10.11124","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4299-3488","authenticated-orcid":false,"given":"Mari","family":"Pesonen","sequence":"first","affiliation":[{"name":"Department of Health and Social Management, University of Eastern Finland, Kuopio, Finland"},{"name":"Finnish Centre for Evidence-Based Health Care: A JBI Centre of Excellence, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0725-1414","authenticated-orcid":false,"given":"Virpi","family":"Jylh\u00e4","sequence":"additional","affiliation":[{"name":"Department of Health and Social Management, University of Eastern Finland, Kuopio, Finland"},{"name":"Finnish Centre for Evidence-Based Health Care: A JBI Centre of Excellence, Helsinki, Finland"},{"name":"Research Centre for Nursing Science and Social and Health Management, Kuopio University Hospital, Wellbeing Services County of North Savo, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5719-5783","authenticated-orcid":false,"given":"Eila","family":"Kankaanp\u00e4\u00e4","sequence":"additional","affiliation":[{"name":"Department of Health and Social Management, University of Eastern Finland, Kuopio, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,11]]},"reference":[{"key":"R1-20250613","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.jval.2012.06.016","article-title":"Conceptualizing a model: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-2","volume":"15","author":"Roberts","year":"2012","journal-title":"Value Health"},{"issue":"9","key":"R4-20250613","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2165\/00019053-200321090-00002","article-title":"Assessing the economic impact of adverse drug effects","volume":"21","author":"Rodr\u00edguez-Monguio","year":"2003","journal-title":"Pharmacoeconomics"},{"issue":"13","key":"R5-20250613","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1056\/NEJM197703312961304","article-title":"Foundations of cost-effectiveness analysis for health and medical practices","volume":"296","author":"Weinstein","year":"1977","journal-title":"N Engl J Med"},{"issue":"3","key":"R6-20250613","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMp1612619","article-title":"Cost-effectiveness analysis 2.0","volume":"376","author":"Neumann","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"R7-20250613","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s41669-020-00250-7","article-title":"National healthcare economic evaluation guidelines: a cross\u2010country comparison","volume":"5","author":"Sharma","year":"2021","journal-title":"Pharmacoecon Open"},{"key":"R9-20250613","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.jval.2014.12.014","article-title":"A systematic review of research guidelines in decision-analytic modeling","volume":"18","author":"Penaloza Ramoz","year":"2015","journal-title":"Value Health"},{"issue":"6","key":"R10-20250613","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.jval.2016.06.001","article-title":"Estimating health-state utility for economic models in clinical studies: an ISPOR Good Research Practices Task Force Report","volume":"19","author":"Wolowacz","year":"2016","journal-title":"Value Health"},{"issue":"3","key":"R11-20250613","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jval.2019.01.004","article-title":"Identification, review, and use of health state utilities in cost-effectiveness models: an ISPOR Good Practices for Outcomes Research Task Force Report","volume":"22","author":"Brazier","year":"2019","journal-title":"Value Health"},{"issue":"3","key":"R12-20250613","first-page":"323","article-title":"Are adverse effects incorporated in economic models? A survey of current practice","volume":"26","author":"Craig","year":"2010","journal-title":"Value Health"},{"issue":"3","key":"R13-20250613","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s40273-022-01232-9","article-title":"Whether and how disutilities of adverse events were used in the economic evaluation of drug therapy for cancer treatment","volume":"41","author":"Lu","year":"2023","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"R14-20250613","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s40273-013-0120-z","article-title":"Including adverse drug events in economic evaluations of anti-tumour necrosis factor-a drugs for adult rheumatoid arthritis: a systematic review of economic decision analytic models","volume":"32","author":"Heather","year":"2014","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"R15-20250613","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s40258-013-0058-5","article-title":"Are the true impacts of adverse events considered in economic models of antineoplastic drugs? A systematic review","volume":"11","author":"Pearce","year":"2013","journal-title":"Appl Health Econ Health Policy"},{"key":"R16-20250613","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/B978-0-444-53480-4.00015-1","article-title":"General aspects of diabetes mellitus","volume":"126","author":"Alam","year":"2014","journal-title":"Handb Clin Neurol"},{"issue":"10397","key":"R17-20250613","first-page":"203","article-title":"Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021","volume":"402","author":"Stafford","year":"2023","journal-title":"Lancet (British edition)"},{"issue":"12","key":"R18-20250613","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1007\/s00125-022-05787-2","article-title":"Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"65","author":"Davies","year":"2022","journal-title":"Diabetologia"},{"issue":"14","key":"R19-20250613","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.93751","article-title":"Diabetic retinopathy: current understanding, mechanisms, and treatment strategies","volume":"2","author":"Duh","year":"2017","journal-title":"JCI insight"},{"issue":"1","key":"R20-20250613","first-page":"28","article-title":"Diabetic macular edema: current understanding, pharmacologic treatment options, and developing therapies. Asia Pac","volume":"7","author":"Miller","year":"2018","journal-title":"J Ophthalmol (Phila)"},{"issue":"9","key":"R21-20250613","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.2337\/dc15-2171","article-title":"Global estimates on the number of people blind or visually impaired by diabetic retinopathy: a meta-analysis from 1990 to 2010","volume":"39","author":"Leasher","year":"2016","journal-title":"Diabetes Care"},{"issue":"3","key":"R22-20250613","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/ICU.0000000000000757","article-title":"Drug-related adverse effects of antivascular endothelial growth factor agents","volume":"32","author":"Iyer","year":"2021","journal-title":"Curr Opin Ophthalmol"},{"issue":"4","key":"R23-20250613","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1159\/000458539","article-title":"Guidelines for the management of diabetic macular edema by the European Society of Retina Specialists (EURETINA)","volume":"237","author":"Schmidt-Erfurth","year":"2017","journal-title":"Ophthalmologica"},{"issue":"3","key":"R24-20250613","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s40273-015-0347-y","article-title":"Cost-effectiveness models in age-related macular degeneration: issues and challenges","volume":"34","author":"Schmier","year":"2016","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"R25-20250613","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s40273-013-0117-7","article-title":"Review of models used in economic analyses of new oral treatments for type 2 diabetes mellitus","volume":"32","author":"Asche","year":"2014","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"R26-20250613","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s40273-015-0374-8","article-title":"A systematic review of cost-effectiveness models in type 1 diabetes mellitus","volume":"34","author":"Henriksson","year":"2016","journal-title":"Pharmacoeconomics"},{"issue":"12","key":"R27-20250613","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.11124\/JBIES-21-00460","article-title":"Adverse drug events in cost-effectiveness analyses of interventions for diabetic conditions: a scoping review protocol","volume":"20","author":"Pesonen","year":"2022","journal-title":"JBI Evid Synth"},{"issue":"7","key":"R29-20250613","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA Extension for Scoping Reviews (PRISMA-ScR): checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann Intern Med"},{"key":"R30-20250613","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"6","key":"R31-20250613","doi-asserted-by":"crossref","first-page":"100852","DOI":"10.1016\/j.cpcardiol.2021.100852","article-title":"First-line treatment with empagliflozin and metformin combination versus standard care for patients with type 2 diabetes mellitus and cardiovascular disease in Qatar. A cost-effectiveness analysis","volume":"47","author":"Abushanab","year":"2022","journal-title":"Curr Probl Cardiol"},{"issue":"1","key":"R32-20250613","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.eprac.2021.07.018","article-title":"Cost-effectiveness of empagliflozin and metformin combination versus standard care as first-line therapy in patients with type 2 diabetes mellitus","volume":"28","author":"Abushanab","year":"2022","journal-title":"Endocr Pract"},{"key":"R33-20250613","doi-asserted-by":"crossref","first-page":"897","DOI":"10.2147\/CEOR.S328433","article-title":"Cost-utility analysis of dapagliflozin compared to sulfonylureas for type 2 diabetes as second-line treatment in Indian healthcare payer\u2019s perspective","volume":"13","author":"Bagepally","year":"2021","journal-title":"Clinicoecon Outcomes Res"},{"issue":"1","key":"R34-20250613","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s13300-019-00736-6","article-title":"Oral semaglutide versus empagliflozin, sitagliptin and liraglutide in the UK: long-term cost-effectiveness analyses based on the PIONEER Clinical Trial Programme","volume":"11","author":"Bain","year":"2020","journal-title":"Diabetes Ther"},{"issue":"8","key":"R35-20250613","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1111\/dom.13318","article-title":"Switching from sitagliptin to liraglutide to manage patients with type 2 diabetes in the UK: a long-term cost-effectiveness analysis","volume":"20","author":"Barnett","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"R36-20250613","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s13300-017-0321-0","article-title":"The cost-effectiveness of dulaglutide 1.5mg versus exenatide QW for the treatment of patients with type 2 diabetes mellitus in France","volume":"9","author":"Basson","year":"2018","journal-title":"Diabetes Ther"},{"issue":"3","key":"R37-20250613","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3111\/13696998.2011.579213","article-title":"Cost-utility of exenatide once weekly compared with insulin glargine in patients with type 2 diabetes in the UK","volume":"14","author":"Beaudet","year":"2011","journal-title":"J Med Econ"},{"key":"R38-20250613","doi-asserted-by":"crossref","first-page":"109152","DOI":"10.1016\/j.diabres.2021.109152","article-title":"Lifetime cost-effectiveness simulation of once-weekly exenatide in type 2 diabetes: a cost-utility analysis based on the EXSCEL trial","volume":"183","author":"Becker","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"issue":"7","key":"R39-20250613","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1111\/dom.13992","article-title":"Cost-effectiveness of dapagliflozin as an adjunct to insulin for the treatment of type 1 diabetes mellitus in the United Kingdom","volume":"22","author":"Bennett","year":"2020","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"R40-20250613","first-page":"20","article-title":"cost-effectiveness of saxagliptin in type 2 diabetes mellitus","volume":"4","author":"Bergenheim","year":"2012","journal-title":"Am J Pharm Benefits"},{"issue":"11","key":"R41-20250613","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.clinthera.2014.07.019","article-title":"Cost-effectiveness of insulin glargine versus sitagliptin in insulin-na\u00efve patients with type 2 diabetes mellitus","volume":"36","author":"Brown","year":"2014","journal-title":"Clinical Therapeutics"},{"issue":"7","key":"R42-20250613","doi-asserted-by":"crossref","first-page":"672","DOI":"10.3111\/13696998.2016.1154567","article-title":"Cost-utility of albiglutide versus insulin lispro, insulin glargine, and sitagliptin for the treatment of type 2 diabetes in the US","volume":"19","author":"Bruhn","year":"2016","journal-title":"J Med Econ"},{"issue":"3","key":"R43-20250613","doi-asserted-by":"crossref","first-page":"217","DOI":"10.5414\/CPP49217","article-title":"Cost-effectiveness of insulin glargine versus NPH insulin for the treatment of type 2 diabetes mellitus, modeling the interaction between hypoglycemia and glycemic control in Switzerland","volume":"49","author":"Br\u00e4ndle","year":"2011","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"4","key":"R45-20250613","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1080\/13696998.2019.1570220","article-title":"Cost-effectiveness analysis of dapagliflozin treatment versus metformin treatment in Chinese population with type 2 diabetes","volume":"22","author":"Cai","year":"2019","journal-title":"J Med Econ"},{"issue":"2","key":"R46-20250613","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s13300-020-00989-6","article-title":"Evaluating the cost-effectiveness of once-weekly semaglutide 1mg versus empagliflozin 25mg for treatment of patients with type 2 diabetes in the UK setting","volume":"12","author":"Capehorn","year":"2021","journal-title":"Diabetes Ther"},{"issue":"2","key":"R47-20250613","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s41669-019-0171-y","article-title":"Cost-effectiveness analysis of exenatide versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus","volume":"4","author":"Capel","year":"2020","journal-title":"Pharmacoecon Open"},{"issue":"3","key":"R48-20250613","doi-asserted-by":"crossref","DOI":"10.4172\/2155-6156.1000653","article-title":"Cost-effectiveness analysis of insulin detemir compared to neutral protamine Hagedorn (NPH) in patients with type 1 and type 2 diabetes mellitus in Portugal","volume":"7","author":"Cardoso","year":"2016","journal-title":"J Diabetes Metab"},{"key":"R49-20250613","first-page":"1","article-title":"A long-term cost-effectiveness analysis of treatments for type 2 diabetes in Portugal: once-weekly semaglutide 1 mg versus once-daily empagliflozin 25 mg. Rev Port Endocrinol","volume":"16","author":"Carvalho","year":"2021","journal-title":"Diabetes Metab"},{"issue":"5","key":"R50-20250613","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1080\/13696998.2018.1434182","article-title":"Comparison of costs and outcomes of dapagliflozin with other glucose-lowering therapy classes added to metformin using a short-term cost-effectiveness modeling the US setting","volume":"21","author":"Chakravarty","year":"2018","journal-title":"J Med Econ"},{"issue":"12","key":"R51-20250613","doi-asserted-by":"crossref","first-page":"585","DOI":"10.12968\/bjhc.2014.20.12.585","article-title":"Cost-effectiveness of bevacizumab for diabetic macular oedema","volume":"20","author":"Chalk","year":"2014","journal-title":"Br J Healthcare Manag"},{"issue":"7","key":"R52-20250613","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1111\/dme.12772","article-title":"The cost-effectiveness of dapagliflozin versus sulfonylurea as an add-on to metformin in the treatment of type 2 diabetes mellitus","volume":"32","author":"Charokopou","year":"2015","journal-title":"Diabet Med"},{"issue":"7","key":"R53-20250613","first-page":"890","article-title":"Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to metformin in the treatment of type 2 diabetes mellitus from a UK healthcare system perspective","volume":"32","author":"Charokopou","year":"2015","journal-title":"BMC Health Serv Res"},{"issue":"3","key":"R54-20250613","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.clinthera.2019.01.003","article-title":"Cost-effectiveness of insulin degludec versus insulin glargine in insulin-naive Chinese patients with type 2 diabetes","volume":"41","author":"Cheng","year":"2019","journal-title":"Clin Ther"},{"issue":"10","key":"R55-20250613","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1080\/03007995.2020.1815686","article-title":"Cost-utility analysis of second-line anti-diabetic therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin","volume":"36","author":"Chien","year":"2020","journal-title":"Curr Med Res Opin"},{"issue":"10","key":"R56-20250613","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.7326\/M21-2941","article-title":"First-line therapy for type 2 diabetes with sodium\u2013glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists. A cost-effectiveness study","volume":"175","author":"Choi","year":"2022","journal-title":"Ann Intern Med"},{"issue":"12","key":"R57-20250613","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1080\/13696998.2016.1203329","article-title":"Cost-effectiveness analysis of exenatide once weekly versus dulaglutide, liraglutide, and lixisenatide for the treatment of type 2 diabetes mellitus: an analysis from the UK NHS perspective","volume":"19","author":"Chuang","year":"2016","journal-title":"J Med Econ"},{"key":"R58-20250613","doi-asserted-by":"crossref","first-page":"750132","DOI":"10.3389\/fmed.2021.750132","article-title":"Cost-effectiveness of conbercept vs. ranibizumab for age-related macular degeneration, diabetic macular edema, and pathological myopia: population-based cohort study and Markov model","volume":"8","author":"Cui","year":"2021","journal-title":"Front Med"},{"issue":"4 Suppl","key":"R59-20250613","first-page":"63","article-title":"Economic evaluation of a fluocinolone acetonide intravitreal implant for patients with DME based on the FAME study","volume":"21","author":"Cutino","year":"2015","journal-title":"Am J Manag Care"},{"issue":"3","key":"R60-20250613","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/j.1464-5491.2011.03429.x","article-title":"Cost-utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in type 2 diabetes mellitus","volume":"29","author":"Davies","year":"2012","journal-title":"Diabet Med"},{"issue":"9","key":"R61-20250613","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1007\/s40273-016-0433-9","article-title":"Cost effectiveness of IDegLira vs. alternative basal insulin intensification therapies in patients with type 2 diabetes mellitus uncontrolled on basal insulin in a UK setting","volume":"34","author":"Davies","year":"2016","journal-title":"Pharmacoeconomics"},{"issue":"10","key":"R62-20250613","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.jval.2017.05.021","article-title":"Basal insulin regimens for adults with type 1 diabetes mellitus: a cost-utility analysis","volume":"20","author":"Dawound","year":"2017","journal-title":"Value Health"},{"issue":"7","key":"R63-20250613","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1007\/s13300-021-01088-w","article-title":"Cost-utility analysis of dapagliflozin as an add-on to standard treatment for patients with type 2 diabetes and high risk of cardiovascular disease in Thailand","volume":"12","author":"Deerochanawong","year":"2021","journal-title":"Diabetes Ther"},{"issue":"11","key":"R64-20250613","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1080\/13696998.2018.1513406","article-title":"Long-term cost-effectiveness analysis shows that IDegLira is associated with improved outcomes and lower costs compared with insulin glargine U100 plus insulin aspart in the US","volume":"21","author":"Dempsey","year":"2018","journal-title":"J Med Econ"},{"issue":"9","key":"R65-20250613","doi-asserted-by":"crossref","first-page":"796","DOI":"10.4158\/EP-2018-0134","article-title":"IDegLira is associated with improved short-term clinical outcomes and cost savings compared with insulin glargine U100 plus insulin aspart in the U.S","volume":"21","author":"Dempsey","year":"2018","journal-title":"Endocr Pract"},{"issue":"11","key":"R66-20250613","doi-asserted-by":"crossref","first-page":"974","DOI":"10.3111\/13696998.2015.1067622","article-title":"Cost-effectiveness analysis of exenatide twice daily (BID) vs insulin glargine once daily (QD) as add-on therapy in Chinese patients with type 2 diabetes mellitus inadequately controlled by oral therapies","volume":"18","author":"Deng","year":"2015","journal-title":"J Med Econ"},{"issue":"8","key":"R67-20250613","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1016\/j.ophtha.2012.01.049","article-title":"Cost-effectiveness analysis of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema","volume":"119","author":"Dewan","year":"2012","journal-title":"Ophthalmology"},{"issue":"5","key":"R68-20250613","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1080\/13696998.2016.1275651","article-title":"The cost-effectiveness of dulaglutide versus liraglutide for the treatment of type 2 diabetes mellitus in Spain in patients with BMI \u226530 kg\/m2","volume":"20","author":"Dilla","year":"2017","journal-title":"J Med Econ"},{"issue":"10","key":"R69-20250613","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1111\/dom.13375","article-title":"The management of type 2 diabetes with fixed-ratio combination insulin degludec\/liraglutide (IDegLira) versus basal-bolus therapy (insulin glargine U100 plus insulin aspart): a short-term cost-effectiveness analysis in the UK setting","volume":"20","author":"Drummond","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"R70-20250613","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1007\/s13300-021-01040-y","article-title":"The cost-effectiveness of empagliflozin versus liraglutide treatment in people with type 2 diabetes and established cardiovascular disease","volume":"12","author":"Ehlers","year":"2021","journal-title":"Diabetes Ther"},{"issue":"1","key":"R71-20250613","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2217\/cer-2021-0169","article-title":"The cost\u2013effectiveness of oral semaglutide versus empagliflozin in type 2 diabetes in Denmark","volume":"11","author":"Ehlers","year":"2022","journal-title":"J Comp Eff Res"},{"issue":"3","key":"R72-20250613","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s13300-022-01221-3","article-title":"The cost-effectiveness of subcutaneous semaglutide versus empagliflozin in type 2 diabetes uncontrolled on metformin alone in Denmark","volume":"13","author":"Ehlers","year":"2022","journal-title":"Diabetes Ther"},{"key":"R73-20250613","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.vhri.2022.07.005","article-title":"Cost-effectiveness of dulaglutide versus liraglutide for management of type 2 diabetes mellitus in Iran","volume":"32","author":"Ekhlasi","year":"2022","journal-title":"Value Health Reg Issues"},{"issue":"1","key":"R74-20250613","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/2191-1991-3-11","article-title":"Treatment of type 2 diabetes with saxagliptin: a pharmacoeconomic evaluation in Argentina","volume":"3","author":"Elgart","year":"2013","journal-title":"Health Econ Rev"},{"issue":"3","key":"R75-20250613","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s41669-021-00317-z","article-title":"Long\u2011term cost effectiveness of oral semaglutide versus empagliflozin and sitagliptin for the treatment of type 2 diabetes in the Swedish setting","volume":"6","author":"Eliasson","year":"2022","journal-title":"Pharmacoecon Open"},{"issue":"3","key":"R76-20250613","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2165\/11597060-000000000-00000","article-title":"Cost effectiveness of saxagliptin and metformin versus sulfonylurea and metformin in the treatment of type 2 diabetes mellitus in Germany. A Cardiff Diabetes Model Analysis","volume":"32","author":"Erhardt","year":"2012","journal-title":"Clin Drug Investig"},{"issue":"12","key":"R77-20250613","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.3111\/13696998.2013.852099","article-title":"Evaluation of the cost-utility of insulin degludec vs insulin glargine in Sweden","volume":"16","author":"Ericsson","year":"2013","journal-title":"J Med Econ"},{"issue":"2","key":"R78-20250613","doi-asserted-by":"crossref","first-page":"e0191953","DOI":"10.1371\/journal.pone.0191953","article-title":"Cost-effectiveness of liraglutide versus lixisenatide as add-on therapies to basal insulin in type 2 diabetes","volume":"13","author":"Ericsson","year":"2018","journal-title":"PLoS One"},{"issue":"10","key":"R79-20250613","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1080\/13696998.2019.1614009","article-title":"Cost-effectiveness of once-weekly semaglutide versus dulaglutide and lixisenatide in patients with type 2 diabetes with inadequate glycemic control in Sweden","volume":"22","author":"Ericsson","year":"2019","journal-title":"J Med Econ"},{"issue":"2","key":"R80-20250613","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s40258-016-0301-y","article-title":"Cost effectiveness of insulin degludec plus liraglutide (IDegLira) in a fixed combination for uncontrolled type 2 diabetes mellitus in Sweden","volume":"15","author":"Ericsson","year":"2017","journal-title":"Appl Health Econ Health Policy"},{"issue":"1","key":"R81-20250613","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1186\/s12913-022-07567-5","article-title":"Cost-effectiveness analysis of dapagliflozin for the treatment of type 2 diabetes mellitus in Spain: results of the DECLARE-TIMI 58 study","volume":"22","author":"Escobar","year":"2022","journal-title":"BMC Health Serv Res"},{"issue":"4","key":"R82-20250613","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/dom.12250","article-title":"Cost-effectiveness of insulin degludec compared with insulin glargine for patients with type 2 diabetes treated with basal insulin \u2013 from the UK health care cost perspective","volume":"16","author":"Evans","year":"2014","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"R83-20250613","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3111\/13696998.2014.971160","article-title":"Cost-effectiveness of insulin degludec compared with insulin glargine in a basal-bolus regimen in patients with type 1 diabetes mellitus in the UK","volume":"18","author":"Evans","year":"2015","journal-title":"J Med Econ"},{"issue":"4","key":"R84-20250613","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s13300-016-0195-6","article-title":"Cost-effectiveness of insulin degludec\/insulin aspart versus biphasic insulin aspart in patients with type 2 diabetes from a Danish health-care perspective","volume":"7","author":"Evans","year":"2016","journal-title":"Diabetes Ther"},{"issue":"2","key":"R85-20250613","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s13300-017-0236-9","article-title":"Cost-effectiveness of insulin degludec versus insulin glargine in adults with type 1 and type 2 diabetes mellitus","volume":"8","author":"Evans","year":"2017","journal-title":"Diabetes Ther"},{"issue":"5","key":"R86-20250613","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1007\/s13300-018-0478-1","article-title":"Cost effectiveness of insulin degludec vs. insulin glargine u100 in type 1 and type 2 diabetes mellitus in a UK setting","volume":"9","author":"Evans","year":"2018","journal-title":"Diabetes Ther"},{"key":"R87-20250613","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1007\/s12325-020-01332-y","article-title":"Cost-effectiveness of insulin degludec versus insulin glargine u300 in the Netherlands: evidence from a randomised controlled trial","volume":"37","author":"Evans","year":"2020","journal-title":"Adv Ther"},{"key":"R88-20250613","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/dom.14892","article-title":"Once-weekly semaglutide versus insulin aspart for the treatment of type 2 diabetes in the UK: a long-term cost-effectiveness analysis based on SUSTAIN 11","volume":"25","author":"Evans","year":"2023","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"R89-20250613","doi-asserted-by":"crossref","first-page":"926","DOI":"10.3111\/13696998.2013.803110","article-title":"The cost-effectiveness of exenatide once weekly compared with exenatide twice daily and insulin glargine for the treatment of patients with type two diabetes and body mass index \u226530 kg\/m2 in Spain","volume":"16","author":"Fonseca","year":"2013","journal-title":"J Med Econ"},{"issue":"7","key":"R90-20250613","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1007\/s12325-022-02156-8","article-title":"The cost-effectiveness of oral semaglutide in Spain: a long-term health economic analysis based on the PIONEER Clinical Trials","volume":"39","author":"Franch-Nadal","year":"2022","journal-title":"Adv Ther"},{"key":"R91-20250613","doi-asserted-by":"crossref","first-page":"255","DOI":"10.2147\/VHRM.S28744","article-title":"Health and economic outcomes for exenatide once weekly, insulin, and pioglitazone therapies in the treatment of type 2 diabetes: a simulation analysis","volume":"8","author":"Gaebler","year":"2012","journal-title":"Vasc Health Risk Manag"},{"issue":"4","key":"R92-20250613","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1007\/s13300-019-0630-6","article-title":"Management of patients with type 2 diabetes with once-weekly semaglutide versus dulaglutide, exenatide ER, liraglutide and lixisenatide: a cost-effectiveness analysis in the Danish setting","volume":"10","author":"G\u00e6de","year":"2019","journal-title":"Diabetes Ther"},{"issue":"4","key":"R93-20250613","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1017\/S0266462312000608","article-title":"Cost-utility analysis of liraglutide versus glimepiride as add-on to metformin in type 2 diabetes patients in China","volume":"8","author":"Gao","year":"2012","journal-title":"Int J Technol Assess Health Care"},{"issue":"1","key":"R94-20250613","doi-asserted-by":"crossref","first-page":"2","DOI":"10.4103\/2078-7685.198336","article-title":"Cost-effectiveness of switching from biphasic human insulin (BHI) to biphasic insulin aspart 30 (BIAsp-30) in type 2 diabetes patients with suboptimal glycaemic control in Singapore","volume":"6","author":"Goh","year":"2015","journal-title":"J Diabetol"},{"issue":"7","key":"R95-20250613","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.endonu.2011.04.005","article-title":"Cost-effectiveness of exenatide versus insulin glargine in Spanish patients with obesity and type 2 diabetes mellitus","volume":"58","author":"Goodall","year":"2011","journal-title":"Endocrinol Nutr"},{"issue":"4","key":"R96-20250613","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s13300-016-0206-7","article-title":"The cost-effectiveness of alogliptin versus sulfonylurea as add-on therapy to metformin in patients with uncontrolled type 2 diabetes mellitus","volume":"7","author":"Gordon","year":"2016","journal-title":"Diabetes Ther"},{"issue":"12","key":"R97-20250613","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1080\/13696998.2016.1208207","article-title":"The cost-effectiveness of exenatide twice daily (BID) vs insulin lispro three times daily (TID) as add-on therapy to titrated insulin glargine in patients with type 2 diabetes","volume":"19","author":"Gordon","year":"2016","journal-title":"J Med Econ"},{"key":"R98-20250613","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/dom.12867","article-title":"Managing glycaemia in older people with type 2 diabetes: a retrospective, primary care-based cohort study, with economic assessment of patient outcomes","volume":"19","author":"Gordon","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"R99-20250613","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1080\/13696998.2019.1681436","article-title":"Assessing the cost-effectiveness of a once-weekly GLP-1 analogue versus an SGLT-2 inhibitor in the Spanish setting: once-weekly semaglutide versus empagliflozin","volume":"23","author":"Gorgojo-Mart\u00ednez","year":"2020","journal-title":"J Med Econ"},{"issue":"5","key":"R100-20250613","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s40261-018-0620-x","article-title":"Cost-effectiveness of empagliflozin for the treatment of patients with type 2 diabetes mellitus at increased cardiovascular risk in Greece","volume":"38","author":"Gourzoulidis","year":"2018","journal-title":"Clin Drug Investig"},{"issue":"4","key":"R101-20250613","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s40261-021-01013-w","article-title":"Cost\u2011effectiveness of empagliflozin compared with dapagliflozin for the treatment of patients with type 2 diabetes mellitus and established cardiovascular disease in Greece","volume":"41","author":"Gourzoulidis","year":"2021","journal-title":"Clin Drug Investig"},{"issue":"2","key":"R102-20250613","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.pcd.2011.09.003","article-title":"Cost-effectiveness of saxagliptin (Onglyza\u00ae) in type 2 diabetes in Sweden","volume":"6","author":"Granstr\u00f6m","year":"2012","journal-title":"Prim Care Diabetes"},{"issue":"1","key":"R103-20250613","first-page":"65","article-title":"The cost-effectiveness of saxagliptin versus NPH insulin when used in combination with other oral antidiabetes agents in the treatment of type 2 diabetes mellitus in Poland. Diabetes Technol","volume":"14","author":"Grzeszczak","year":"2012","journal-title":"Therap"},{"issue":"4","key":"R104-20250613","doi-asserted-by":"crossref","first-page":"654","DOI":"10.3111\/13696998.2012.670677","article-title":"Long-term cost-consequence analysis of exenatide once weekly vs sitagliptin or pioglitazone for the treatment of type 2 diabetes patients in the United States","volume":"15","author":"Guillermin","year":"2012","journal-title":"J Med Econ"},{"issue":"4","key":"R105-20250613","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3111\/13696998.2014.991791","article-title":"An analysis of the cost-effectiveness of switching from biphasic human insulin 30, insulin glargine, or neutral protamine Hagedorn to biphasic insulin aspart 30 in people with type 2 diabetes","volume":"18","author":"Gupta","year":"2015","journal-title":"J Med Econ"},{"issue":"10","key":"R106-20250613","doi-asserted-by":"crossref","first-page":"808","DOI":"10.3111\/13696998.2015.1049542","article-title":"Cost-effectiveness of saxagliptin vs glimepiride as a second-line therapy added to metformin in type 2 diabetes in China","volume":"18","author":"Gu","year":"2015","journal-title":"J Med Econ"},{"issue":"11","key":"R107-20250613","doi-asserted-by":"crossref","first-page":"E0165629","DOI":"10.1371\/journal.pone.0165629","article-title":"Cost-effectiveness of dapagliflozin versus acarbose as a monotherapy in type 2 diabetes in China","volume":"11","author":"Gu","year":"2016","journal-title":"PLoS One"},{"issue":"11","key":"R108-20250613","doi-asserted-by":"crossref","first-page":"e0167190","DOI":"10.1371\/journal.pone.0167190","article-title":"Cost-effectiveness of saxagliptin versus acarbose as second-line therapy in type 2 diabetes in China","volume":"11","author":"Gu","year":"2016","journal-title":"PLoS One"},{"issue":"12","key":"R109-20250613","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1111\/dom.12991","article-title":"Cost-effectiveness of exenatide twice daily vs insulin glargine as add-on therapy to oral antidiabetic agents in patients with type 2 diabetes in China","volume":"19","author":"Gu","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"R110-20250613","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1186\/s12916-020-01837-x","article-title":"Choice across 10 pharmacologic combination strategies for type 2 diabetes: a cost-effectiveness analysis","volume":"18","author":"Gu","year":"2020","journal-title":"BMC Med"},{"issue":"4","key":"R111-20250613","first-page":"455","article-title":"Cost-effectiveness of oral semaglutide added to current antihyperglycemic treatment for type 2 diabetes","volume":"27","author":"Guzauskas","year":"2021","journal-title":"J Manag Care Spec Pharm"},{"issue":"7","key":"R112-20250613","doi-asserted-by":"crossref","first-page":"663","DOI":"10.3111\/13696998.2016.1154566","article-title":"Cost-effectiveness of ranibizumab in the treatment of visual impairment due to diabetic macular edema","volume":"19","author":"Haig","year":"2016","journal-title":"J Med Econ"},{"issue":"3","key":"R113-20250613","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1080\/13696998.2019.1669613","article-title":"Cost-effectiveness of switching to insulin degludec from other basal insulins in real-world clinical practice in Italy","volume":"23","author":"Haldrup","year":"2020","journal-title":"J Med Econ"},{"key":"R114-20250613","doi-asserted-by":"crossref","first-page":"1011624","DOI":"10.3389\/fphar.2022.1011624","article-title":"Insulin degludec\/liraglutide versus its monotherapy on T2D patients: a lifetime cost-utility analysis in China","volume":"13","author":"Han","year":"2022","journal-title":"Front Pharmacol"},{"issue":"3","key":"R115-20250613","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1080\/13696998.2019.1666855","article-title":"Cost-effectiveness of ranibizumab and afilbercept to treat diabetic macular edema from a US perspective: analysis of 2-year Protocol T data","volume":"23","author":"Holekamp","year":"2020","journal-title":"J Med Econ"},{"issue":"3","key":"R116-20250613","doi-asserted-by":"crossref","first-page":"230","DOI":"10.3111\/13696998.2014.985788","article-title":"An analysis of the cost-effectiveness of starting insulin detemir in insulin-na\u00efve people with type 2 diabetes","volume":"18","author":"Home","year":"2015","journal-title":"J Med Econ"},{"key":"R117-20250613","doi-asserted-by":"crossref","first-page":"480","DOI":"10.3389\/fphar.2019.00480","article-title":"Cost-effectiveness of canagliflozin versus dapagliflozin added to metformin in patients with type 2 diabetes in China","volume":"10","author":"Hou","year":"2019","journal-title":"Front Pharmacol"},{"key":"R118-20250613","doi-asserted-by":"crossref","first-page":"936703","DOI":"10.3389\/fpubh.2022.936703","article-title":"Cost-effectiveness analysis of dapagliflozin plus standard treatment for patients with type 2 diabetes and high risk of cardiovascular disease in China","volume":"10","author":"Huang","year":"2022","journal-title":"Front Public Health"},{"issue":"8","key":"R119-20250613","doi-asserted-by":"crossref","first-page":"573","DOI":"10.3111\/13696998.2015.1038271","article-title":"Cost-effectiveness of once daily GLP-1 receptor agonist lixisenatide compared to bolus insulin both in combination with basal insulin for the treatment of patients with type 2 diabetes in Norway","volume":"18","author":"Huetson","year":"2015","journal-title":"J Med Econ"},{"issue":"4","key":"R120-20250613","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s13300-017-0266-3","article-title":"Modeling the long-term cost-effectiveness of IDegLira in patients with type 2 diabetes who are failing to meet glycemic targets on basal insulin alone in the Netherlands","volume":"8","author":"Hunt","year":"2017","journal-title":"Diabetes Ther"},{"issue":"7","key":"R121-20250613","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.clinthera.2017.05.354","article-title":"Long-term cost-effectiveness of two GLP-1 receptor agonists for the treatment of type 2 diabetes mellitus in the Italian setting: liraglutide versus lixisenatide","volume":"39","author":"Hunt","year":"2017","journal-title":"Clin Ther"},{"issue":"7","key":"R122-20250613","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1080\/13696998.2017.1301943","article-title":"Evaluation of the long-term cost-effectiveness of IDegLira versus liraglutide added to basal insulin for patients with type 2 diabetes failing to achieve glycemic control on basal insulin in the USA","volume":"20","author":"Hunt","year":"2017","journal-title":"J Med Econ"},{"issue":"3","key":"R123-20250613","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s13300-017-0251-x","article-title":"IDegLira versus insulin glargine U100: a long-term cost-effectiveness analysis in the US setting","volume":"8","author":"Hunt","year":"2017","journal-title":"Diabetes Ther"},{"issue":"6","key":"R124-20250613","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/dom.12890","article-title":"Evaluation of the long-term cost-effectiveness of liraglutide vs lixisenatide for treatment of type 2 diabetes mellitus in the UK setting","volume":"19","author":"Hunt","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"R125-20250613","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s13300-016-0219-2","article-title":"Evaluating the long-term cost-effectiveness of daily administered GLP-1 receptor agonists for the treatment of type 2 diabetes in the United Kingdom","volume":"8","author":"Hunt","year":"2017","journal-title":"Diabetes Ther"},{"issue":"1","key":"R126-20250613","doi-asserted-by":"crossref","first-page":"e000705","DOI":"10.1136\/bmjdrc-2019-000705","article-title":"Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands","volume":"7","author":"Hunt","year":"2019","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"1","key":"R127-20250613","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s40258-020-00603-7","article-title":"Cost\u2011utility analysis of dapagliflozin versus saxagliptin treatment as monotherapy or combination therapy as add\u2011on to metformin for treating type 2 diabetes mellitus","volume":"19","author":"Hu","year":"2021","journal-title":"Appl Health Econ Health Policy"},{"key":"R128-20250613","doi-asserted-by":"crossref","first-page":"701446","DOI":"10.3389\/fphar.2021.701446","article-title":"Exploring the appropriate price of semaglutide for type 2 diabetes patients based on cost-utility analysis in China","volume":"12","author":"Hu","year":"2021","journal-title":"Front Pharmacol"},{"issue":"2","key":"R129-20250613","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/dom.14881","article-title":"Cost-utility analysis of semaglutide for type 2 diabetes after its addition to the National Medical Insurance System in China","volume":"25","author":"Hu","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"R130-20250613","doi-asserted-by":"crossref","first-page":"831364","DOI":"10.3389\/fphar.2022.831364","article-title":"Cost-utility analysis of once-weekly semaglutide, dulaglutide, and exenatide for type 2 diabetes patients receiving metformin-based background therapy in China","volume":"13","author":"Hu","year":"2022","journal-title":"Front Pharmacol"},{"issue":"12","key":"R131-20250613","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1001\/jamaophthalmol.2019.4284","article-title":"Five-year cost-effectiveness of intravitreous ranibizumab therapy vs panretinal photocoagulation for treating proliferative diabetic retinopathy: a secondary analysis of a randomized clinical trial","volume":"137","author":"Hutton","year":"2019","journal-title":"JAMA Ophthalmol"},{"key":"R132-20250613","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.jval.2017.08.464","article-title":"Cost-effectiveness analysis of empagliflozin in the treatment of T2D with previous cardiovascular disease in Italy","volume":"20","author":"Iannazzo","year":"2017","journal-title":"Value Health"},{"issue":"7","key":"R133-20250613","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1007\/s13300-022-01270-8","article-title":"Cost-effectiveness analysis of initiating type 2 diabetes therapy with a sodium-glucose cotransporter 2 inhibitor versus conventional therapy in Japan","volume":"13","author":"Igarashi","year":"2022","journal-title":"Diabetes Ther"},{"issue":"5","key":"R134-20250613","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1080\/13696998.2018.1431918","article-title":"The cost-effectiveness of dulaglutide versus insulin glargine for the treatment of type 2 diabetes mellitus in Japan","volume":"21","author":"Ishii","year":"2018","journal-title":"J Med Econ"},{"issue":"11","key":"R135-20250613","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1080\/13696998.2020.1805454","article-title":"Real-world cost-effectiveness of insulin degludec in type 1 and type 2 diabetes mellitus from a Swedish 1-year and long-term perspective","volume":"23","author":"Jendle","year":"2020","journal-title":"J Med Econ"},{"issue":"4","key":"R136-20250613","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s41669-019-0131-6","article-title":"Cost effectiveness of once\u2011weekly semaglutide versus once\u2011weekly dulaglutide in the treatment of type 2 diabetes in Canada","volume":"3","author":"Johansen","year":"2019","journal-title":"Pharmacoecon Open"},{"issue":"5","key":"R137-20250613","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1007\/s12325-020-01337-7","article-title":"Evaluating the long-term cost-effectiveness of once weekly semaglutide versus once-daily liraglutide for the treatment of type 2 diabetes in the UK","volume":"37","author":"Johansen","year":"2020","journal-title":"Adv Ther"},{"issue":"10","key":"R138-20250613","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1016\/j.clinthera.2019.07.016","article-title":"Cost-effectiveness analysis of empagliflozin in Japan based on results from the Asian subpopulation in the EMPA-REG OUTCOME Trial","volume":"41","author":"Kaku","year":"2019","journal-title":"Clin Ther"},{"issue":"11","key":"R139-20250613","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1111\/dme.14076","article-title":"Cost-effectiveness analysis of empagliflozin treatment in people with type 2 diabetes and established cardiovascular disease in the EMPA-REG OUTCOME trial","volume":"36","author":"Kansal","year":"2019","journal-title":"Diabet Med"},{"issue":"2","key":"R140-20250613","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s13300-014-0080-0","article-title":"Cost\u2013utility analysis of glucagon-like peptide-1 agonists compared with dipeptidyl peptidase-4 inhibitors or neutral protamine Hagedorn basal insulin as add-on to metformin in type 2 diabetes in Sweden","volume":"5","author":"Kiadaliri","year":"2014","journal-title":"Diabetes Ther"},{"issue":"16","key":"R141-20250613","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1503\/cmaj.110178","article-title":"Cost-effectiveness of second-line antihyperglycemic therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin","volume":"183","author":"Klarenbach","year":"2011","journal-title":"CMAJ"},{"issue":"7","key":"R142-20250613","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12962-016-0056-1","article-title":"Cost-utility of ranibizumab versus aflibercept for treating Greek patients with visual impairment due to diabetic macular edema. Cost-utility of ranibizumab versus aflibercept for treating Greek patients with visual impairment due to diabetic macular edema","volume":"14","author":"Kourlaba","year":"2016","journal-title":"Cost Eff Resour Alloc"},{"issue":"1","key":"R143-20250613","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12962-017-0082-7","article-title":"Cost effectiveness of vildagliptin versus glimepiride as add-on treatment to metformin for the treatment of diabetes mellitus type 2 patients in Greece","volume":"15","author":"Kousoulakou","year":"2017","journal-title":"Cost Eff Resour Alloc"},{"issue":"3","key":"R144-20250613","first-page":"171","article-title":"Cost-effectiveness analysis of dapagliflozin versus canagliflozin in treatment of type 2 diabetes mellitus","volume":"12","author":"Krishnamoorthy","year":"2022","journal-title":"J Appl Pharm Sci"},{"issue":"6","key":"R145-20250613","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1007\/s13300-017-0323-y","article-title":"Cost-effectiveness of IDegLira versus insulin intensification regimens for the treatment of adults with type 2 diabetes in the Czech Republic","volume":"8","author":"Kvapil","year":"2017","journal-title":"Diabetes Ther"},{"issue":"3","key":"R146-20250613","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1007\/s13300-018-0426-0","article-title":"Cost-effectiveness of insulin degludec versus insulin glargine U100 in patients with type 1 and type 2 diabetes mellitus in Serbia","volume":"9","author":"Lalic","year":"2018","journal-title":"Diabetes Ther"},{"issue":"4","key":"R147-20250613","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1007\/s13300-019-0635-1","article-title":"Short-term cost-effectiveness of switching to insulin degludec in Japanese patients with type 2 diabetes receiving basal\u2013bolus therapy","volume":"10","author":"Langer","year":"2019","journal-title":"Diabetes Ther"},{"issue":"4","key":"R148-20250613","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1080\/03007995.2016.1277194","article-title":"Cost-effectiveness of switching to insulin degludec from other basal insulins: evidence from Swedish real-world data","volume":"33","author":"Landstedt-Hallin","year":"2017","journal-title":"Curr Med Res Opin"},{"key":"R149-20250613","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.vhri.2016.10.006","article-title":"Cost effectiveness of dulaglutide compared with liraglutide and glargine in type 2 diabetes mellitus patients in Colombia","volume":"14","author":"Lasalvia","year":"2017","journal-title":"Value Health Reg Issues"},{"issue":"6","key":"R150-20250613","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1080\/14737167.2022.2044310","article-title":"Cost-effectiveness of dapagliflozin compared to DPP-4 inhibitors as combination therapy with metformin in the treatment of type 2 diabetes mellitus without established cardiovascular disease in Colombia","volume":"22","author":"Lasalvia","year":"2022","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"1","key":"R151-20250613","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12962-019-0180-9","article-title":"Insulin glargine compared to neutral protamine Hagedorn (NPH) insulin in patients with type-2 diabetes uncontrolled with oral anti-diabetic agents alone in Hong Kong: a cost-effectiveness analysis","volume":"17","author":"Lau","year":"2019","journal-title":"Cost Eff Resour Alloc"},{"issue":"5","key":"R152-20250613","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1185\/03007995.2011.559444","article-title":"Cost-effectiveness of liraglutide versus rosiglitazone, both in combination with glimepiride in treatment of type 2 diabetes in the US","volume":"27","author":"Lee","year":"2011","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"R153-20250613","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3111\/13696998.2012.716111","article-title":"Long-term clinical and economic outcomes associated with liraglutide versus sitagliptin therapy when added to metformin in the treatment of type 2 diabetes: a CORE Diabetes Model analysis","volume":"15","author":"Lee","year":"2012","journal-title":"J Med Econ"},{"issue":"9","key":"R154-20250613","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/j.ophtha.2018.02.038","article-title":"Cost evaluation of early vitrectomy versus panretinal photocoagulation and intravitreal ranibizumab for proliferative diabetic retinopathy","volume":"125","author":"Lin","year":"2018","journal-title":"Ophthalmol"},{"key":"R155-20250613","first-page":"12","article-title":"Cost-effectiveness of dipeptidylpeptidase-4 inhibitors added to metformin in patients with type 2 diabetes in China","author":"Lin","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"R157-20250613","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s13300-022-01336-7","article-title":"Long-term cost-effectiveness of subcutaneous once-weekly semaglutide versus polyethylene glycol loxenatide for treatment of type 2 diabetes mellitus in China","volume":"14","author":"Liu","year":"2023","journal-title":"Diabetes Ther"},{"key":"R158-20250613","doi-asserted-by":"crossref","first-page":"1016937","DOI":"10.3389\/fpubh.2022.1016937","article-title":"Cost-effectiveness of insulin degludec\/insulin aspart versus biphasic insulin aspart in Chinese population with type 2 diabetes","volume":"10","author":"Luo","year":"2022","journal-title":"Front Public Health"},{"issue":"1","key":"R159-20250613","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s13300-018-0542-x","article-title":"Once-weekly semaglutide versus once-daily liraglutide for the treatment of type 2 diabetes: a long-term cost-effectiveness analysis in Estonia","volume":"10","author":"Malkin","year":"2019","journal-title":"Diabetes Ther"},{"issue":"8","key":"R160-20250613","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1007\/s12325-019-00965-y","article-title":"the management of type 2 diabetes with once-weekly semaglutide versus dulaglutide: a long-term cost-effectiveness analysis in Slovakia","volume":"36","author":"Malkin","year":"2019","journal-title":"Adv Ther"},{"key":"R161-20250613","doi-asserted-by":"crossref","first-page":"108759","DOI":"10.1016\/j.diabres.2021.108759","article-title":"The long-term cost-effectiveness of oral semaglutide in the Netherlands based on the PIONEER 2, 3 and 4 randomized controlled trials","volume":"175","author":"Malkin","year":"2021","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"R162-20250613","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13098-022-00801-4","article-title":"The long-term cost-effectiveness of oral semaglutide versus empagliflozin and dulaglutide in Portugal","volume":"14","author":"Malkin","year":"2022","journal-title":"Diabetol Metab Syndr"},{"issue":"10","key":"R163-20250613","doi-asserted-by":"crossref","first-page":"4427","DOI":"10.1007\/s12325-020-01464-1","article-title":"Evaluation of the long-term cost-effectiveness of once-weekly semaglutide versus dulaglutide and sitagliptin in the Spanish setting","volume":"37","author":"Mart\u00edn","year":"2020","journal-title":"Adv Ther"},{"issue":"12","key":"R164-20250613","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1007\/s13300-021-01159-y","article-title":"Cost-effectiveness of iGlarLixi in people with type 2 diabetes mellitus suboptimally controlled on basal insulin plus metformin in the UK","volume":"12","author":"McCrimmon","year":"2021","journal-title":"Diabetes Ther"},{"issue":"12","key":"R165-20250613","doi-asserted-by":"crossref","first-page":"3231","DOI":"10.1007\/s13300-021-01156-1","article-title":"Cost-effectiveness of iGlarLixi versus iDegLira in type 2 diabetes mellitus inadequately controlled by GLP-1 receptor agonists and oral antihyperglycemic therapy","volume":"12","author":"McCrimmon","year":"2021","journal-title":"Diabetes Ther"},{"issue":"6","key":"R166-20250613","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1007\/s13300-022-01267-3","article-title":"Cost-effectiveness of iGlarLixi versus Premix BIAsp 30 in patients with type 2 diabetes suboptimally controlled by basal insulin in the UK","volume":"13","author":"McCrimmon","year":"2022","journal-title":"Diabetes Ther"},{"issue":"12","key":"R167-20250613","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1111\/dom.14162","article-title":"Assessing the cost-effectiveness of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes mellitus: a comprehensive economic evaluation using clinical trial and real-world evidence","volume":"22","author":"McEwan","year":"2020","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"R168-20250613","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1111\/dom.14308","article-title":"The cost-effectiveness of dapagliflozin in treating high-risk patients with type 2 diabetes mellitus: an economic evaluation using data from the DECLARE-TIMI 58 trial","volume":"23","author":"McEwan","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"R169-20250613","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/dom.13871","article-title":"Comparison of lixisenatide in combination with basal insulin vs other insulin regimens for the treatment of patients with type 2 diabetes inadequately controlled by basal insulin: systematic review, network meta-analysis and cost-effectiveness analysis","volume":"22","author":"Men","year":"2020","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"R170-20250613","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1007\/s13300-020-00857-3","article-title":"Lixisenatide for type 2 diabetes mellitus patients inadequately controlled on oral antidiabetic drugs: a mixed-treatment comparison meta-analysis and cost\u2013utility analysis","volume":"11","author":"Men","year":"2020","journal-title":"Diabetes Ther"},{"key":"R171-20250613","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.2147\/DMSO.S266901","article-title":"Empagliflozin in type 2 diabetes mellitus patients with high cardiovascular risk: a model-based cost-utility analysis in China","volume":"13","author":"Men","year":"2020","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"2","key":"R172-20250613","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s13300-013-0044-9","article-title":"Incretin therapy for type 2 diabetes in Spain: a cost-effectiveness analysis of liraglutide versus sitagliptin","volume":"4","author":"Mezquita Raya","year":"2013","journal-title":"Diabetes Ther"},{"issue":"6","key":"R173-20250613","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1080\/14737167.2017.1345628","article-title":"Cost-effectiveness analysis of insulin degludec compared with insulin glargine u100 for the management of type 1 and type 2 diabetes mellitus - from the Spanish National Health System perspective","volume":"17","author":"Mezquita-Raya","year":"2017","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"2","key":"R174-20250613","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s13300-017-0239-6","article-title":"Liraglutide versus lixisenatide: long-term cost-effectiveness of GLP-1 receptor agonist therapy for the treatment of type 2 diabetes in Spain","volume":"8","author":"Mezquita-Raya","year":"2017","journal-title":"Diabetes Ther"},{"issue":"3","key":"R175-20250613","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2217\/cer-2019-0174","article-title":"Cost\u2013effectiveness analysis of intravitreal aflibercept in the treatment of diabetic macular edema in China","volume":"9","author":"Ming","year":"2020","journal-title":"J Comp Eff Res"},{"issue":"5","key":"R176-20250613","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1136\/bjophthalmol-2011-300726","article-title":"Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the RESTORE trial","volume":"96","author":"Mitchell","year":"2012","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"R177-20250613","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12962-022-00401-z","article-title":"Cost-effectiveness of dexamethasone compared with aflibercept in na\u00efve diabetic macular edema","volume":"20","author":"Montes Rodr\u00edguez","year":"2022","journal-title":"Cost Eff Resour Alloc"},{"issue":"4","key":"R178-20250613","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s13300-015-0143-x","article-title":"Cost-effectiveness analysis of insulin detemir compared to neutral protamine Hagedorn (NPH) in Patients with Type 1 and Type 2 Diabetes Mellitus in Spain","volume":"6","author":"Morales","year":"2015","journal-title":"Diabetes Ther"},{"key":"R179-20250613","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1007\/s00125-022-05832-0","article-title":"Projecting the incidence and costs of major cardiovascular and kidney complications of type 2 diabetes with widespread SGLT2i and GLP-1 RA use: a cost-effectiveness analysis","volume":"66","author":"Morton","year":"2023","journal-title":"Diabetologia"},{"key":"R180-20250613","first-page":"8","article-title":"Cost-effectiveness of canagliflozin versus sitagliptin as add-on to metformin in patients with type 2 diabetes mellitus in Mexico. Value Health Reg","volume":"8","author":"Neslusan","year":"2015","journal-title":"Issues"},{"issue":"2","key":"R181-20250613","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s13300-018-0371-y","article-title":"Cost-effectiveness analysis of canagliflozin 300mg versus dapagliflozin 10mg added to metformin in patients with type 2 diabetes in the United States","volume":"9","author":"Neslusan","year":"2018","journal-title":"Diabetes Ther"},{"issue":"2","key":"R182-20250613","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.jdiacomp.2017.10.006","article-title":"Cost-utility of empagliflozin in patients with type 2 diabetes at high cardiovascular risk","volume":"32","author":"Nguyen","year":"2018","journal-title":"J Diabetes Complications"},{"key":"R183-20250613","doi-asserted-by":"crossref","first-page":"562023","DOI":"10.3389\/fpubh.2020.562023","article-title":"Cost-effectiveness of gliclazide-based intensive glucose control vs. standard glucose control in type 2 diabetes mellitus. An economic analysis of the ADVANCE Trial in Vietnam","volume":"8","author":"Nguyen-Thi","year":"2020","journal-title":"Front Public Health"},{"issue":"1","key":"R184-20250613","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12962-020-00208-w","article-title":"Economic evaluation of dapagliflozin versus metformin in Chinese patients whose diabetes is inadequately controlled with diet and exercise","volume":"18","author":"Nian","year":"2020","journal-title":"Cost Eff Resour Alloc"},{"issue":"3","key":"R195-20250613","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/dom.14921","article-title":"Model-based predictions on health benefits and budget impact of implementing empagliflozin in people with type 2 diabetes and established cardiovascular disease","volume":"25","author":"Nilsson","year":"2023","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"R196-20250613","first-page":"294","article-title":"Cost-effectiveness and budget impact of saxagliptine as additional therapy to metformin for the treatment of diabetes mellitus type 2 in the Brazilian private health system","volume":"58","author":"Nita","year":"2012","journal-title":"Rev Assoc Med Bras"},{"issue":"4\/5","key":"R197-20250613","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1108\/IJHCQA-02-2019-0042","article-title":"The cost-effectiveness of insulin analogs and regular insulin for diabetes control: a case study in Iran. The cost-effectiveness of insulin analogs and regular insulin for diabetes control: a case study in Iran","volume":"33","author":"Pakdaman","year":"2020","journal-title":"Int J Health Care Qual Assur"},{"issue":"5","key":"R198-20250613","first-page":"231","article-title":"Cost-effectiveness of DPP-4 inhibitor and SGLT2 inhibitor combination therapy for type 2 diabetes","volume":"25","author":"Pawaskar","year":"2019","journal-title":"Am J Manag Care"},{"key":"R199-20250613","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1111\/dom.13618","article-title":"Cost-effectiveness of intensification with sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes on metformin and sitagliptin vs direct intensification with insulin in the United Kingdom","volume":"21","author":"Pawaskar","year":"2019","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"R200-20250613","doi-asserted-by":"crossref","first-page":"269","DOI":"10.37765\/ajmc.2021.88728","article-title":"Cost-effectiveness of intensification with SGLT2 inhibitors for type 2 diabetes","volume":"27","author":"Pawaskar","year":"2021","journal-title":"Am J Manag Care"},{"issue":"7","key":"R201-20250613","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1111\/dom.14708","article-title":"Cost-effectiveness of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors among patients with type 2 diabetes with and without established cardiovascular diseases: a model-based simulation analysis using 10-year real-world data and targeted literature review","volume":"24","author":"Peng","year":"2022","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"R202-20250613","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s13300-015-0103-5","article-title":"Cost-effectiveness analysis of incretin therapy for type 2 diabetes in Spain: 1.8 mg liraglutide versus sitagliptin","volume":"6","author":"P\u00e9rez","year":"2015","journal-title":"Diabetes Ther"},{"issue":"3","key":"R203-20250613","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s40258-016-0228-3","article-title":"Long-term cost-effectiveness of insulin glargine versus neutral protamine Hagedorn insulin for type 2 diabetes in Thailand","volume":"14","author":"Permsuwan","year":"2016","journal-title":"Appl Health Econ Health Policy"},{"key":"R204-20250613","doi-asserted-by":"crossref","first-page":"521","DOI":"10.2147\/CEOR.S113559","article-title":"Cost-effectiveness of dipeptidyl peptidase-4 inhibitor monotherapy in elderly type 2 diabetes patients in Thailand","volume":"8","author":"Permsuwan","year":"2016","journal-title":"Clinicoecon Outcomes Res"},{"issue":"9","key":"R205-20250613","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1080\/13696998.2017.1347792","article-title":"Cost-effectiveness of insulin detemir versus insulin glargine for Thai type 2 diabetes from a payer\u2019s perspective","volume":"20","author":"Permsuwan","year":"2017","journal-title":"J Med Econ"},{"issue":"1","key":"R206-20250613","doi-asserted-by":"crossref","first-page":"18","DOI":"10.7326\/M13-0768","article-title":"Cost-effectiveness of treatment of diabetic macular edema","volume":"160","author":"Pershing","year":"2014","journal-title":"Ann Intern Med"},{"key":"R207-20250613","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1111\/aos.14745","article-title":"Cost-effectiveness of dexamethasone and triamcinolone for the treatment of diabetic macular oedema in Finland: a Markov-model","volume":"99","author":"Pesonen","year":"2021","journal-title":"Acta Ophthalmol"},{"issue":"2","key":"R208-20250613","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3111\/13696998.2012.713879","article-title":"Health economic evaluation of insulin glargine vs NPH insulin in intensified conventional therapy for type 1 diabetes in Germany","volume":"15","author":"Pfohl","year":"2012","journal-title":"J Med Econ"},{"issue":"1","key":"R209-20250613","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12913-018-3804-4","article-title":"Cost-effectiveness of fluocinolone acetonide implant (ILUVIEN (R)) in UK patients with chronic diabetic macular oedema considered insufficiently responsive to available therapies","volume":"19","author":"Pochopien","year":"2019","journal-title":"BMC Health Serv Res"},{"key":"R210-20250613","doi-asserted-by":"crossref","first-page":"605","DOI":"10.2147\/CEOR.S218746","article-title":"value for money in the treatment of patients with type 2 diabetes mellitus: assessing the long-term cost-effectiveness of IDegLira versus iGlarLixi in Italy","volume":"11","author":"P\u00f6hlmann","year":"2019","journal-title":"Clinicoecon Outcomes Res"},{"issue":"2","key":"R211-20250613","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s13300-019-0569-7","article-title":"Treating patients with type 2 diabetes mellitus uncontrolled on basal insulin in the Czech Republic: cost-effectiveness of IDegLira versus iGlarLixi","volume":"10","author":"P\u00f6hlmann","year":"2019","journal-title":"Diabetes Ther"},{"issue":"1","key":"R212-20250613","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3111\/13696998.2010.541045","article-title":"The cost effectiveness of rapid-acting insulin aspart compared with human insulin in type 2 diabetes patients: an analysis from the Japanese third-party payer perspective","volume":"14","author":"Pollock","year":"2011","journal-title":"J Med Econ"},{"issue":"12","key":"R213-20250613","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1007\/s12325-012-0065-1","article-title":"UK analysis of the cost-effectiveness of Humalog Mix75\/25 and Mix50\/50 versus long-acting basal insulin","volume":"29","author":"Pollock","year":"2012","journal-title":"Adv Ther"},{"issue":"4","key":"R214-20250613","doi-asserted-by":"crossref","first-page":"766","DOI":"10.3111\/13696998.2012.675890","article-title":"A long-term analysis evaluating the cost-effectiveness of biphasic insulin lispro mix 75\/25 and mix 50\/50 versus long-acting basal insulin analogs in the United States","volume":"15","author":"Pollock","year":"2012","journal-title":"J Med Econ"},{"key":"R215-20250613","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2147\/DMSO.S156739","article-title":"Evaluating the cost-effectiveness of insulin detemir versus neutral protamine Hagedorn insulin in patients with type 1 or type 2 diabetes in the UK using a short-term modeling approach","volume":"11","author":"Pollock","year":"2018","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"3","key":"R216-20250613","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1007\/s13300-018-0430-4","article-title":"DEVOTE 5: evaluating the short-term cost-utility of insulin degludec versus insulin glargine U100 in basal-bolus regimens for type 2 diabetes in the UK","volume":"9","author":"Pollock","year":"2018","journal-title":"Diabetes Ther"},{"issue":"7","key":"R217-20250613","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1111\/dom.13730","article-title":"Short-term cost-utility of degludec versus glargine U100 for patients with type 2 diabetes at high risk of hypoglycaemia and cardiovascular events: a Canadian setting (DEVOTE 9)","volume":"21","author":"Pollock","year":"2019","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"R218-20250613","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2217\/cer-2018-0073","article-title":"A cost-utility analysis of dulaglutide versus insulin glargine as third-line therapy for type 2 diabetes in Canada","volume":"8","author":"Pollock","year":"2019","journal-title":"J Comp Eff Res"},{"issue":"5","key":"R219-20250613","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s40258-019-00494-3","article-title":"Long-term cost-effectiveness of insulin degludec versus insulin glargine U100 in the UK: evidence from the basal-bolus subgroup of the DEVOTE Trial (DEVOTE 16)","volume":"17","author":"Pollock","year":"2019","journal-title":"Appl Health Econ Health Policy"},{"issue":"3","key":"R220-20250613","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1080\/13696998.2016.1245663","article-title":"A short-term cost-utility analysis of insulin degludec versus insulin glargine U100 in patients with type 1 or type 2 diabetes in Denmark","volume":"20","author":"Pollock","year":"2017","journal-title":"J Med Econ"},{"key":"R221-20250613","doi-asserted-by":"crossref","first-page":"749","DOI":"10.2147\/CEOR.S143127","article-title":"Cost-effectiveness analysis of IDegLira versus basal-bolus insulin for patients with type 2 diabetes in the Slovak health system","volume":"9","author":"Psota","year":"2017","journal-title":"Clinicoecon Outcomes Res"},{"issue":"6","key":"R222-20250613","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1007\/s13300-019-00701-3","article-title":"Cost-effectiveness analysis of empagliflozin in comparison to sitagliptin and saxagliptin based on cardiovascular outcome trials in patients with type 2 diabetes and established cardiovascular disease","volume":"10","author":"Ramos","year":"2019","journal-title":"Diabetes Ther"},{"issue":"9","key":"R223-20250613","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1007\/s13300-020-00883-1","article-title":"Long-term cost-effectiveness analyses of empagliflozin versus oral semaglutide, in addition to metformin, for the treatment of type 2 diabetes in the UK","volume":"11","author":"Ramos","year":"2020","journal-title":"Diabetes Ther"},{"issue":"11","key":"R224-20250613","doi-asserted-by":"crossref","first-page":"781","DOI":"10.2217\/cer-2020-0071","article-title":"Cost-effectiveness of empagliflozin compared with liraglutide based on cardiovascular outcome trials in type II diabetes","volume":"9","author":"Ramos","year":"2020","journal-title":"J Comp Eff Res"},{"issue":"1","key":"R225-20250613","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12962-021-00299-z","article-title":"Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China","volume":"19","author":"Ramos","year":"2021","journal-title":"Cost Eff Resour Alloc"},{"issue":"6","key":"R226-20250613","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1111\/dom.13660","article-title":"Evaluating the long-term cost-effectiveness of fixed-ratio combination insulin degludec\/liraglutide (IDegLira) for type 2 diabetes in Spain based on real-world clinical evidence","volume":"21","author":"Raya","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"R227-20250613","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2147\/CEOR.S82556","article-title":"Cost-effectiveness of ranibizumab versus aflibercept in the treatment of visual impairment due to diabetic macular edema: a UK healthcare perspective","volume":"7","author":"R\u00e9gnier","year":"2015","journal-title":"Clinicoecon Outcomes Res"},{"issue":"3","key":"R228-20250613","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/dom.14268","article-title":"Cost-effectiveness analysis of empagliflozin versus sitagliptin as second-line therapy for treatment in patients with type 2 diabetes in the United States","volume":"23","author":"Reifsnider","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"R229-20250613","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2020-001313","article-title":"Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease","volume":"9","author":"Reifsnider","year":"2021","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"4","key":"R230-20250613","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/dom.14625","article-title":"Cost-effectiveness of second-line empagliflozin versus liraglutide for type 2 diabetes in the United States","volume":"24","author":"Reifsnider","year":"2022","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"R231-20250613","doi-asserted-by":"crossref","first-page":"468","DOI":"10.3111\/13696998.2013.768999","article-title":"Cost-effectiveness of insulin detemir compared with NPH insulin in people with type 2 diabetes in Denmark, Finland, Norway, and Sweden","volume":"16","author":"Ridderstr\u00e5le","year":"2013","journal-title":"J Med Econ"},{"issue":"11","key":"R233-20250613","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1016\/j.clinthera.2021.08.015","article-title":"Lifetime cost-effectiveness of oral semaglutide versus dulaglutide and liraglutide in patients with type 2 diabetes inadequately controlled with oral antidiabetics","volume":"43","author":"Risebrough","year":"2021","journal-title":"Clin Ther"},{"key":"R234-20250613","first-page":"33","article-title":"Pharmacoeconomic analysis of sitagliptin\/metformin for the treatment of type 2 diabetes mellitus: a cost-effectiveness study. Value Health Reg","volume":"26","author":"Rojas","year":"2021","journal-title":"Issues"},{"issue":"8","key":"R235-20250613","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1001\/jamaophthalmol.2016.1669","article-title":"Cost-effectiveness of aflibercept, bevacizumab, and ranibizumab for diabetic macular edema treatment: analysis from the Diabetic Retinopathy Clinical Research Network Comparative Effectiveness Trial","volume":"134","author":"Ross","year":"2016","journal-title":"JAMA Ophthalmol"},{"issue":"2","key":"R236-20250613","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3111\/13696998.2015.1100998","article-title":"Evaluation of the long-term cost-effectiveness of liraglutide therapy for patients with type 2 diabetes in France","volume":"19","author":"Roussel","year":"2016","journal-title":"J Med Econ"},{"issue":"10","key":"R237-20250613","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1007\/s13300-022-01301-4","article-title":"Long-term cost-effectiveness analysis of once-weekly semaglutide versus dulaglutide in patients with type 2 diabetes with inadequate glycemic control in China","volume":"13","author":"Ruan","year":"2022","journal-title":"Diabetes Ther"},{"issue":"12","key":"R238-20250613","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1111\/dom.13026","article-title":"Projected long-term outcomes in patients with type 1 diabetes treated with fast-acting insulin aspart vs conventional insulin aspart in the UK setting","volume":"19","author":"Russell-Jones","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"R239-20250613","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s12902-019-0460-6","article-title":"Cost-effectiveness of insulin degludec versus insulin glargine U100 in adults with type 1 and type 2 diabetes mellitus in Bulgaria","volume":"19","author":"Russel-Szymczyk","year":"2019","journal-title":"BMC Endocr Disord"},{"issue":"1","key":"R240-20250613","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.pcd.2014.04.007","article-title":"Cost-effectiveness of dapagliflozin (Forxiga (R)) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries","volume":"9","author":"Sabale","year":"2015","journal-title":"Prim Care Diabetes"},{"issue":"2","key":"R241-20250613","first-page":"151","article-title":"Cost-effectiveness of canagliflozin versus sitagliptin when added to metformin and sulfonylurea in type 2 diabetes in Canada","volume":"23","author":"Sabapathy","year":"2016","journal-title":"J Popul Ther Clin Pharmacol"},{"issue":"6","key":"R242-20250613","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2217\/cer-2020-0284","article-title":"Cost-effectiveness analysis of empagliflozin compared with glimepiride in patients with type 2 diabetes in China","volume":"10","author":"Salem","year":"2021","journal-title":"J Comp Eff Res"},{"issue":"2","key":"R243-20250613","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3111\/13696998.2012.708691","article-title":"Long-term cost-utility analysis of exenatide once weekly versus insulin glargine for the treatment of type 2 diabetes patients in the US","volume":"15","author":"Samyshkin","year":"2012","journal-title":"J Med Econ"},{"issue":"2","key":"R244-20250613","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.diabres.2014.08.024","article-title":"An analysis of the short- and long-term cost-effectiveness of starting biphasic insulin aspart 30 in insulin-na\u00efve people with poorly controlled type 2 diabetes","volume":"106","author":"Shafie","year":"2014","journal-title":"Diabetes Res Clin Pract"},{"key":"R245-20250613","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2147\/CEOR.S244884","article-title":"Cost-effectiveness of insulin glargine and insulin detemir in the basal regimen for na\u00efve insulin patients with type 2 diabetes mellitus (T2DM) in Malaysia","volume":"12","author":"Shafie","year":"2020","journal-title":"Clinicoecon Outcomes Res"},{"key":"R246-20250613","doi-asserted-by":"crossref","first-page":"791","DOI":"10.2147\/CEOR.S180067","article-title":"Cost-effectiveness and budget impact of liraglutide in type 2 diabetes patients with elevated cardiovascular risk: a US-managed care perspective","volume":"10","author":"Shah","year":"2018","journal-title":"Clinicoecon Outcomes Res"},{"issue":"2","key":"R247-20250613","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1080\/03007995.2016.1257978","article-title":"Cost-effectiveness analysis of dapagliflozin versus glimepiride as monotherapy in a Chinese population with type 2 diabetes mellitus","volume":"33","author":"Shao","year":"2017","journal-title":"Curr Med Res Opin"},{"issue":"9","key":"R248-20250613","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1007\/s13300-022-01300-5","article-title":"Cost effectiveness of iGlarLixi versus Premix BIAsp 30 in people with type 2 diabetes suboptimally controlled by basal insulin in the US","volume":"13","author":"Shao","year":"2022","journal-title":"Diabetes Ther"},{"issue":"5","key":"R249-20250613","doi-asserted-by":"crossref","first-page":"977","DOI":"10.3111\/13696998.2012.692340","article-title":"Long-term cost-effectiveness of insulin detemir versus NPH insulin in type 2 diabetes in Sweden","volume":"15","author":"Smith-Palmer","year":"2012","journal-title":"J Med Econ"},{"issue":"4","key":"R250-20250613","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s40258-022-00726-z","article-title":"Cost\u2011effectiveness of once\u2011weekly semaglutide 1 mg versus canagliflozin 300 mg in patients with type 2 diabetes mellitus in a Canadian setting","volume":"20","author":"Stafford","year":"2022","journal-title":"Appl Health Econ Health Policy"},{"issue":"9","key":"R251-20250613","doi-asserted-by":"crossref","first-page":"658","DOI":"10.3111\/13696998.2014.933110","article-title":"Cost-effectiveness of add-on treatments to metformin in a Swedish setting: liraglutide vs sulphonylurea or sitagliptin","volume":"17","author":"Steen Carlsson","year":"2014","journal-title":"J Med Econ"},{"issue":"9","key":"R252-20250613","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.ophtha.2013.02.002","article-title":"Cost-effectiveness of various interventions for newly diagnosed diabetic macular edema","volume":"120","author":"Stein","year":"2013","journal-title":"Ophthalmology"},{"issue":"5","key":"R253-20250613","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1007\/s13300-019-00683-2","article-title":"Meta-analysis and cost-effectiveness analysis of insulin glargine 100 U\/mL versus insulin degludec for the treatment of type 2 diabetes in China","volume":"10","author":"Su","year":"2019","journal-title":"Diabetes Ther"},{"key":"R254-20250613","article-title":"Cost-utility analysis of saxagliptin\/dapagliflozin versus gliclazide and insulin glargine: economic implications of the outcomes of the CVD-Real Studies I and II","volume":"13","author":"Torre","year":"2020","journal-title":"Health Serv Insights"},{"key":"R255-20250613","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1186\/1472-6963-14-419","article-title":"Cost-effectiveness analysis of liraglutide versus sitagliptin or exenatide in patients with inadequately controlled Type 2 diabetes on oral antidiabetic drugs in Greece","volume":"14","author":"Tzanetakos","year":"2014","journal-title":"BMC Health Serv Res"},{"issue":"8","key":"R256-20250613","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s40261-016-0410-2","article-title":"Cost-effectiveness of dapagliflozin as add-on to metformin for the treatment of type 2 diabetes mellitus in Greece","volume":"36","author":"Tzanetakos","year":"2016","journal-title":"Clin Drug Investig"},{"issue":"1","key":"R257-20250613","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s40261-017-0586-0","article-title":"Cost effectiveness of exenatide once weekly versus insulin glargine and liraglutide for the treatment of type 2 diabetes mellitus in Greece","volume":"38","author":"Tzanetakos","year":"2018","journal-title":"Clin Drug Investig"},{"issue":"1","key":"R258-20250613","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1177\/1403494810379290","article-title":"Evaluation of the long-term cost-effectiveness of insulin detemir compared with neutral protamine Hagedorn insulin in patients with type 1 diabetes using a basal-bolus regimen in Sweden","volume":"39","author":"Valentine","year":"2011","journal-title":"Scand J Public Health"},{"issue":"11","key":"R259-20250613","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1016\/j.clinthera.2011.09.022","article-title":"Evaluating the long-term cost-effectiveness of liraglutide versus exenatide BID in patients with type 2 diabetes who fail to improve with oral antidiabetic agents","volume":"33","author":"Valentine","year":"2011","journal-title":"Clin Ther"},{"issue":"3","key":"R260-20250613","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1464-5491.2011.03461.x","article-title":"Evaluating the cost-effectiveness of reduced mild hypoglycaemia in subjects with type 1 diabetes treated with insulin detemir or NPH insulin in Denmark, Sweden, Finland and the Netherlands","volume":"29","author":"Valentine","year":"2012","journal-title":"Diabet Med"},{"issue":"3","key":"R261-20250613","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s40258-018-0379-5","article-title":"Treating type 1 diabetes mellitus with a rapid-acting analog insulin regimen vs. regular human insulin in Germany: a long-term cost-effectiveness evaluation","volume":"16","author":"Valentine","year":"2018","journal-title":"Appl Health Econ Health Policy"},{"key":"R262-20250613","doi-asserted-by":"crossref","first-page":"e14371","DOI":"10.1111\/dme.14371","article-title":"The cost-effectiveness of dapagliflozin compared to DPP-4 inhibitors in the treatment of type 2 diabetes mellitus in the Netherlands","volume":"38","author":"Van der Linden","year":"2021","journal-title":"Diabet Med"},{"issue":"2","key":"R263-20250613","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s40261-013-0155-0","article-title":"Cost effectiveness of adding dapagliflozin to insulin for the treatment of type 2 diabetes mellitus in the Netherlands","volume":"34","author":"van Haalen","year":"2014","journal-title":"Clin Drug Investig"},{"issue":"3","key":"R264-20250613","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s13300-017-0250-y","article-title":"Cost-effectiveness of liraglutide versus dapagliflozin for the treatment of patients with type 2 diabetes mellitus in the UK","volume":"8","author":"Vega-Hernandez","year":"2017","journal-title":"Diabetes Ther"},{"key":"R265-20250613","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/dom.13564","article-title":"Evaluation of the long-term cost-effectiveness of once-weekly semaglutide versus dulaglutide for treatment of type 2 diabetes mellitus in the UK","volume":"21","author":"Viljoen","year":"2019","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"R266-20250613","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1007\/s10198-022-01514-1","article-title":"The long\u2011term cost\u2011effectiveness of once\u2011weekly semaglutide 1 mg vs. dulaglutide 3 mg and 4.5 mg in the UK","volume":"24","author":"Viljoen","year":"2023","journal-title":"Eur J Health Econ"},{"issue":"7","key":"R267-20250613","doi-asserted-by":"crossref","first-page":"499","DOI":"10.3111\/13696998.2014.912986","article-title":"Cost-effectiveness of metformin plus vildagliptin compared with metformin plus sulphonylurea for the treatment of patients with type 2 diabetes mellitus: a Portuguese healthcare system perspective","volume":"17","author":"Viriato","year":"2014","journal-title":"J Med Econ"},{"key":"R268-20250613","doi-asserted-by":"crossref","first-page":"1341963","DOI":"10.1155\/2019\/1341963","article-title":"Cost-effectiveness of bariatric surgery versus medication therapy for obese patients with type 2 diabetes in China: a Markov Analysis","volume":"2019","author":"Wan","year":"2019","journal-title":"J Diabetes Res"},{"key":"R269-20250613","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1007\/s13300-020-00852-8","article-title":"Cost-effectiveness analysis of linagliptin in Japan based on results from the Asian subpopulation in the CARMELINA Trial","volume":"11","author":"Watada","year":"2020","journal-title":"Diabetes Ther"},{"issue":"1","key":"R270-20250613","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1016\/j.jval.2011.11.018","article-title":"Cost-effectiveness of switching patients with type 2 diabetes from insulin glargine to insulin detemir in Chinese setting: a health economic model based on the PREDICTIVE Study","volume":"15","author":"Yang","year":"2012","journal-title":"Value Health"},{"issue":"6","key":"R271-20250613","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0156393","article-title":"Long-term effectiveness and cost-effectiveness of metformin combined with liraglutide or exenatide for type 2 diabetes mellitus based on the CORE Diabetes Model Study","volume":"11","author":"Zhang","year":"2016","journal-title":"PLoS One"},{"issue":"15","key":"R272-20250613","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.2217\/cer-2021-0016","article-title":"Cost-effectiveness of empagliflozin versus weekly semaglutide as add-on therapy for type 2 diabetes","volume":"10","author":"Zupa","year":"2021","journal-title":"J Comp Eff Res"},{"issue":"9","key":"R273-20250613","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0162441","article-title":"The health economic value of changes in glycaemic control, weight and rates of hypoglycaemia in type 1 diabetes mellitus","volume":"11","author":"McEwan","year":"2016","journal-title":"PLoS One"},{"issue":"1","key":"R274-20250613","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12962-015-0038-8","article-title":"Validation of the UKPDS 82 risk equations within the Cardiff Diabetes Model","volume":"13","author":"McEwan","year":"2015","journal-title":"Cost Eff Resour Alloc"},{"issue":"6","key":"R275-20250613","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.jval.2014.07.007","article-title":"Validation of the IMS CORE Diabetes Model","volume":"17","author":"McEwan","year":"2014","journal-title":"Value in Health"},{"issue":"9","key":"R276-20250613","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1007\/s00125-013-2940-y","article-title":"UKPDS Outcomes Model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82","volume":"56","author":"Hayes","year":"2013","journal-title":"Diabetologia"},{"issue":"10","key":"R277-20250613","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0110235","article-title":"Validation of the IHE cohort model of type 2 diabetes and the impact of choice of macrovascular risk equations","volume":"9","author":"Lundqvist","year":"2014","journal-title":"PLoS One"},{"issue":"8","key":"R278-20250613","doi-asserted-by":"crossref","first-page":"749","DOI":"10.2217\/cer-2018-0001","article-title":"Development and validation of a health policy model of type 2 diabetes in Chinese setting","volume":"7","author":"Wu","year":"2018","journal-title":"J Comp Eff Res"},{"issue":"3","key":"R279-20250613","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s40273-016-0471-3","article-title":"Validation of the economic and health outcomes model of type 2 diabetes mellitus (ECHO-T2DM)","volume":"35","author":"Willis","year":"2017","journal-title":"PharmacoEconomics"},{"issue":"7","key":"R280-20250613","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.jval.2016.12.001","article-title":"The Prime Diabetes Model: novel methods for estimating long-term clinical and cost outcomes in type 1 diabetes mellitus","volume":"20","author":"Valentine","year":"2017","journal-title":"Value Health"},{"issue":"11","key":"R281-20250613","doi-asserted-by":"crossref","first-page":"3102","DOI":"10.2337\/diacare.26.11.3102","article-title":"Validation of the Archimedes Diabetes Model","volume":"26","author":"Eddy","year":"2003","journal-title":"Diabetes Care"},{"issue":"9","key":"R282-20250613","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1007\/s11136-014-0712-x","article-title":"Diminishing marginal disutility of hypoglycaemic events: results from a time trade-off survey in five countries","volume":"23","author":"Lauridsen","year":"2014","journal-title":"Qual Life Res"},{"issue":"3","key":"R283-20250613","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1586\/14737167.2014.912562","article-title":"Challenges to time trade-off utility assessment methods: when should you consider alternative approaches?","volume":"14","author":"Boye","year":"2014","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"6","key":"R284-20250613","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1080\/14737167.2016.1246962","article-title":"How to prepare a systematic review of economic evaluations for clinical practice guidelines: database selection and search strategy development (part 2\/3)","volume":"16","author":"Thielen","year":"2016","journal-title":"Expert Rev Pharmacoecon Outcomes Res"}],"container-title":["JBI Evidence Synthesis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.11124\/JBIES-23-00511","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T12:35:41Z","timestamp":1786451741000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.11124\/JBIES-23-00511"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,29]]},"references-count":267,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.11124\/jbies-23-00511","relation":{},"ISSN":["2689-8381"],"issn-type":[{"value":"2689-8381","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,29]]}}}